In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / ...
HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments ...
In a comprehensive Genomic Press research article, scientists have uncovered remarkable insights into how the earliest brain connections shape infant emotional development, potentially offering new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback